Clincosm LogoSign in Get a demo

Hepatocellular Carcinoma (HCC)

Showing 1 - 25 of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma (HCC) Trial (Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE))

Not yet recruiting
  • Hepatocellular Carcinoma (HCC)
  • (no location specified)
Sep 11, 2023

Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

Not yet recruiting
  • Melanoma
  • +5 more
  • INCB 99280 with Ipilimumab
  • (no location specified)
Jun 9, 2023

Radiomics, Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE) Trial in Guangzhou (Sorafenib,

Active, not recruiting
  • Radiomics
  • +4 more
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Jun 5, 2023

Hepatocellular Carcinoma (HCC) Trial in Taiwan (Chidamide, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma (HCC)
  • Kaohsiung, Taiwan
  • +4 more
Mar 14, 2023

Hepatocellular Carcinoma (HCC) Trial in Beijing (¹³C-Octanoate Breath Test)

Completed
  • Hepatocellular Carcinoma (HCC)
  • ¹³C-Octanoate Breath Test
  • Beijing, China
  • +1 more
Dec 19, 2022

Chronic Liver Disease, Hepatocellular Carcinoma (HCC) Trial in Toronto (13C Sodium Octanoate)

Terminated
Has Results
  • Chronic Liver Disease
  • Hepatocellular Carcinoma (HCC)
  • 13C Sodium Octanoate
  • Toronto, Ontario, Canada
    Toronto General Hospital
Dec 19, 2022

FAST (Focused Abbreviated Screening Technique)-MRI Study

Enrolling by invitation
  • Hepatocellular Carcinoma (HCC)
  • Liver Cirrhosis
    • New York, New York
      Icahn School of Medicine at Mount Sinai
    Oct 17, 2022

    Hepatocellular Carcinoma (HCC) Trial in Taiwan, United States (IA therapy of HCC with CSR02-Fab-TF)

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • IA therapy of HCC with CSR02-Fab-TF
    • Saint Louis, Missouri
    • +6 more
    Aug 16, 2022

    Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Tumors Trial in Boston (ET140203 T Cells)

    Recruiting
    • Hepatoblastoma
    • +5 more
    • ET140203 T Cells
    • Boston, Massachusetts
      Dana-Farber/Boston Children's Cancer and Blood Disorders Center
    Aug 12, 2022

    Hepatocellular Carcinoma (HCC) Trial in Worldwide (Fisogatinib (BLU-554))

    Active, not recruiting
    • Hepatocellular Carcinoma (HCC)
    • Fisogatinib (BLU-554)
    • Rialto, California
    • +40 more
    Aug 12, 2022

    Hepatocellular Carcinoma (HCC) Trial in Worldwide (Tislelizumab)

    Completed
    • Hepatocellular Carcinoma (HCC)
    • Hefei, Anhui, China
    • +64 more
    Jul 20, 2022

    Hepatocellular Carcinoma (HCC) Trial in Japan, Taiwan (ERY974, Tocilicumab, Atezolizumab)

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Chiba-shi, Chiba, Japan
    • +5 more
    Jun 22, 2022

    Hepatocellular Carcinoma (HCC), Second Line Treatment Trial in Germany (Cabozantinib Oral Tablet)

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Second Line Treatment
    • Cabozantinib Oral Tablet
    • Bad Saarow, Germany
    • +9 more
    Mar 29, 2022

    Multimodal Machine Learning Characterization of Solid Tumors

    Recruiting
    • Adenocarcinoma of Prostate
    • +5 more
    • Boston, Massachusetts
    • +1 more
    Apr 4, 2022

    NSCLC (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC) Trial in Canada, United States

    Active, not recruiting
    • Non-small Cell Lung Cancer (NSCLC)
    • +2 more
    • Beverly Hills, California
    • +5 more
    Mar 28, 2022

    Hepatocellular Carcinoma (HCC) Trial in Beijing (Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE))

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Expanded Activated Lymphocytes (EAL)
    • transarterial chemoembolization (TACE)
    • Beijing, Beijing, China
      Chinese PLA General Hospital
    Feb 4, 2022

    Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma Trial in Ann Arbor (drug, device, radiation, diagnostic

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Unresectable Hepatocellular Carcinoma
    • Ann Arbor, Michigan
      University of Michigan Rogel Cancer Center
    Dec 16, 2021

    Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer Trial in London, Oxford (HMBD-001)

    Recruiting
    • Bladder Cancer
    • +13 more
    • London, United Kingdom
    • +1 more
    Dec 13, 2021

    Hepatocellular Carcinoma (HCC) Trial in Nancy, Paris (Pexastimogene Devacirepvec (Pexa Vec), Nivolumab)

    Terminated
    Has Results
    • Hepatocellular Carcinoma (HCC)
    • Nancy, France
    • +1 more
    Oct 21, 2021

    Hepatocellular Carcinoma (HCC), Cholangiocarcinoma Trial in Multiple Locations (Physician's choice according to patient's

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Cholangiocarcinoma
    • Physician's choice according to patient's needs.
    • Multiple Locations, Germany
      Multiple sites all over germany
    Aug 27, 2021

    Hepatocellular Carcinoma (HCC) Trial in Indianapolis (Yttrium-90 Radiation Segmentectomy, Stereotactic Body Radiation Therapy)

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Yttrium-90 Radiation Segmentectomy
    • Stereotactic Body Radiation Therapy
    • Indianapolis, Indiana
      Indiana University
    Aug 27, 2021

    Hepatocellular Carcinoma (HCC) Trial in China (Camrelizumab, Rivoceranib (Apatinib))

    Recruiting
    • Hepatocellular Carcinoma (HCC)
    • Chongqing, Chongqing, China
    • +5 more
    Aug 16, 2021

    Hepatocellular Carcinoma (HCC) Trial in Worldwide (Tislelizumab, Sorafenib)

    Active, not recruiting
    • Hepatocellular Carcinoma (HCC)
    • Coronado, California
    • +142 more
    Jul 27, 2021

    Hepatocellular Carcinoma (HCC) Trial (LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin)

    Withdrawn
    • Hepatocellular Carcinoma (HCC)
    • LC Bead LUMI™ (Radiopaque (RO) Bead) loaded with doxorubicin
    • (no location specified)
    Apr 19, 2021

    Hepatocellular Carcinoma (HCC) Trial in Beijing, Nanjing (Icaritin)

    Completed
    • Hepatocellular Carcinoma (HCC)
    • Beijing, Beijing, China
    • +2 more
    Jan 25, 2021